Whether patent holders marketing branded drugs may assume that the very act of filing of an MA application by generic companies result in patent infringement is one of the hottest issues at the…
In the UK, the signal “Another train coming” flashes when there is more than one railway line over an automatic crossing and another train is approaching. If you have avoided the first train, you…
The IP deadline management system should ensure that the system is noting the new deadlines for European Divisional Applications properly.
According to revised Rule 36(1) and Rule 36(2) being…
[gallery columns="2" orderby="title"]
The protected product within the meaning of Article 3 (a) of SPC Regulation (EEC) No. 1768/92 must be a product claimed as such in the basic patent.
Daiichi…
On any view, the world of international patents is fast-paced and constantly changing in shape. Barely a week goes by without an important development from a major national Court or the EPO in a…
As the Supreme Court had held for European Patents (SC 6 March 2009 Boston Scientific/Medinol), the Court of Appeal now affirms that the so-called Spiro/Flamco doctrine, which set strict requirements…
The District Court of The Hague holds the Dutch part of Eli Lilly's olanzapine patent and SPC invalid because the substance olanzapine has been directly and unambiguously disclosed in a prior art…
On 1 March 2010, Commercial Court number 1 of Pamplona handed down a judgement dismissing a declaratory non-infringement action filed by L.C. against N. The Court rejected the claim in its entirety,…
In this case, the Board of Appeal had to decide whether a claim containing a feature for which the description contained erroneous figures only met the requirements of Article 83 EPC (sufficiency of…
The Supreme Court confirmed the Court of Appeal's decision that the certification of the status of creator of a technical achievement is an indispensable condition for monetary compensation of an…
